Nicole L Byers
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations(2019)277 cited
- → Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients(2020)267 cited
- → Infections in baricitinib clinical trials for patients with active rheumatoid arthritis(2020)91 cited
- → Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways(2020)61 cited
- → Multicentre randomized controlled trial of structured transition on diabetes care management compared to standard diabetes care in adolescents and young adults with type 1 diabetes (Transition Trial)(2013)41 cited
- → Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis(2018)37 cited
- → Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients(2020)30 cited
- Learning with/ from others: Teachers' perceptions of peer collaboration and group work in the OBE classroom.(2008)
- → O4 Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus(2020)